Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Multicenter, Single-Arm Study Verifying the Benefit of Trastuzumab Deruxtecan (T-DXd) in AI Re-Scored HER2-Ultralow (HER2UL) Unresectable or Metastatic Breast Cancer Manually Scored as HER2-Null

NCT07782086 is registered in ClinicalTrials.gov with Shuangyue Liu as lead sponsor.

NCT NCT07782086
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07782086 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Multicenter, Single-Arm Study Verifying the Benefit of Trastuzumab Deruxtecan (T-DXd) in AI Re-Scored HER2-Ultralow (HER2UL) Unresectable or Metastatic Breast Cancer Manually Scored as HER2-Null
Lead sponsor
Shuangyue Liu
Phase
Not applicable
Overall status
Not yet recruiting
Start date
September 7, 2026
Completion date
December 31, 2029
Enrollment
30 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer